Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmSTU:AL21 26 ROC (Joel Greenblatt) % is -208.16% as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 26/100. Among 665 Healthcare Providers & Services companies, Veradigm ranks worse than 150375.79% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Veradigm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -208.16%.
The historical rank and industry rank for Veradigm's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:AL21's ROC (Joel Greenblatt) % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12.48 * Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
Veradigm's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for Veradigm's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AL21 vs WEAV, PHR, SOPH: ROC (Joel Greenblatt) % Comparison
For the Health Information Services subindustry, Veradigm's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Veradigm's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is one times the annual (Dec. 2022) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -208.16% mean?
Veradigm (STU:AL21) has a ROC (Joel Greenblatt) % of -208.16% as of Dec. 2022. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 665 companies in the Healthcare Providers & Services industry.
Is Veradigm's ROC (Joel Greenblatt) % too high?
Veradigm's current ROC (Joel Greenblatt) % is -208.16%. Based on the distribution chart, Veradigm ranks #999999 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's ROC (Joel Greenblatt) % compare to WEAV and PHR?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 665 companies for ROC (Joel Greenblatt) %. This places Veradigm in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 12.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.48, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current ROC (Joel Greenblatt) % is -208.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current ROC (Joel Greenblatt) % of -208.16%. The current ROC (Joel Greenblatt) % is -208.16%. Veradigm's overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Veradigm (STU:AL21), the current ROC (Joel Greenblatt) % is -208.16% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
26GF Score
Get the complete analysis for STU:AL21
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AL21 has been successfully added to your 
